J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Gains of chromosome 8 are confined to mesenchymal components in pleuropulmonary blastoma.
TL;DR: It is indicated that clonal proliferation in pleuropulmonary blastoma is restricted to the malignant mesenchymal elements, supporting the notion that the epithelial components of this tumor are non-neoplastic.
Journal ArticleDOI
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
Yvonne de Jong,Annemiek M. van Maldegem,Adrián Mariño-Enríquez,Danielle de Jong,Johnny Suijker,Inge H. Briaire-de Bruijn,Alwine B. Kruisselbrink,Anne-Marie Cleton-Jansen,Karoly Szuhai,Hans Gelderblom,Jonathan A. Fletcher,Judith V.M.G. Bovée +11 more
TL;DR: Combination treatments demonstrated ABT-737 synergism with cisplatin as well as doxorubicin as shown by induction of apoptosis and reduction in cell proliferation, indicating that combining the inhibition of Bcl-2 family members with conventional chemotherapy can be a possible therapeutic strategy for patients with mesenchymal chondrosarcoma.
Journal ArticleDOI
Insulin receptor activation in solitary fibrous tumours.
Y. Li,Q. Chang,Brian P. Rubin,Christopher D.M. Fletcher,Thomas W. Morgan,Steven J. Mentzer,David J. Sugarbaker,Jonathan A. Fletcher,Sheng Xiao +8 more
TL;DR: Uniform activation of the insulin receptor (IR) pathway in SFTs, which are mesenchymal tumours frequently associated with hypoglycaemia, is reported and studies suggest that IR activation plays an oncogenic role in S FTs.
Journal ArticleDOI
Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors
T. R. J. Evans,Jeffrey A. Morgan,A. D. Van Den Abbeele,I. R. J. McPherson,Suzanne George,D. Crawford,J. M. Mastrullo,Su-Chun Cheng,Jonathan A. Fletcher,George D. Demetri +9 more
TL;DR: This is the first study to evaluate the safety, tolerability, and pharmacologic profiles of BMS-354825 in pts with treatment-resistant GIST and other refractory solid tumors.
Journal ArticleDOI
Targeting SALL4 by entinostat in lung cancer.
Kol Jia Yong,Ailing Li,Wen-Bin Ou,Wen-Bin Ou,Clarice Hong,Wenxiu Zhao,Fei Wang,Hiro Tatetsu,Benedict Yan,Lihua Qi,Jonathan A. Fletcher,Henry Yang,Ross A. Soo,Daniel G. Tenen,Daniel G. Tenen,Li Chai +15 more
TL;DR: It is reported for the first time that entinostat can target SALL4-positive lung cancer, and this lays the foundation for future clinical studies evaluating the therapeutic efficacy of ent inostat in Sall4- positive lung cancer patients.